BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31967739)

  • 21. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
    Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 25. Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.
    Ge J; Xia Y; Sun Z; Zhang L; Li X; Li L; Wang X; Zhang X; Li Z; Nan F; Wan W; Xu D; Ding J; Fu X; Zhang M
    Leuk Lymphoma; 2022 Jun; 63(6):1369-1374. PubMed ID: 34989286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of failure of diffuse large B‑cell lymphoma patients after involved-site radiotherapy.
    Holzhäuser E; Berlin M; Wollschläger D; Bezold T; Mayer A; Heß G; Schmidberger H
    Strahlenther Onkol; 2017 Dec; 193(12):1014-1023. PubMed ID: 28748453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients.
    Nyilas R; Farkas B; Bicsko RR; Magyari F; Pinczes LI; Illes A; Gergely L
    Int J Hematol; 2019 Sep; 110(3):331-339. PubMed ID: 31228077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy.
    Li C; Ma X; Pan Z; Lv F; Xia Z; Xue K; Zhang Q; Ji D; Cao J; Hong X; Guo Y
    Leuk Res; 2018 Nov; 74():80-85. PubMed ID: 30316031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
    Vargo JA; Gill BS; Balasubramani GK; Beriwal S
    J Clin Oncol; 2015 Nov; 33(32):3710-7. PubMed ID: 26261253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
    Barraclough A; Alzahrani M; Ettrup MS; Bishton M; van Vliet C; Farinha P; Gould C; Birch S; Sehn LH; Sovani V; Ward MS; Augustson B; Biccler J; Connors JM; Scott DW; Gandhi MK; Savage KJ; El-Galaly T; Villa D; Cheah CY
    Blood Adv; 2019 Jul; 3(13):2013-2021. PubMed ID: 31285189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.
    Alzahrani M; El-Galaly TC; Hutchings M; Hansen JW; Loft A; Johnsen HE; Iyer V; Wilson D; Sehn LH; Savage KJ; Connors JM; Gascoyne RD; Johansen P; Clasen-Linde E; Brown P; Villa D
    Ann Oncol; 2016 Jun; 27(6):1095-1099. PubMed ID: 27002106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.
    El Karak F; Bou-Orm IR; Ghosn M; Kattan J; Farhat F; Ibrahim T; Jreige M; El Cheikh J; Haidar M
    PLoS One; 2017; 12(1):e0170299. PubMed ID: 28099514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
    Dorth JA; Prosnitz LR; Broadwater G; Diehl LF; Beaven AW; Coleman RE; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):762-7. PubMed ID: 22420972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.
    Pilorge S; Harel S; Ribrag V; Larousserie F; Willems L; Franchi P; Legoff M; Biau D; Anract P; Roux C; Blanc-Autran E; Delarue R; Gisselbrecht C; Ketterer N; Recher C; Bonnet C; Peyrade F; Haioun C; Tilly H; Salles G; Brice P; Bouscary D; Deau B; Tamburini J
    Leuk Lymphoma; 2016 Dec; 57(12):2820-2826. PubMed ID: 27118302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
    Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
    J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry.
    Greenbaum U; Levi I; Madmoni O; Lior Y; Al-Athamen K; Perry ZH; Hatzkelzon L; Shubinsky G
    Leuk Lymphoma; 2019 Oct; 60(10):2477-2482. PubMed ID: 31014136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
    Qiao W; Zhao J; Xing Y; Wang C; Wang T
    Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.